Rentosertib, an AI-generated small molecule targeting Traf2- and Nck-interacting kinase, was safe and improved FVC in ...

SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF ...

SAN FRANCISCO — Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with progressive pulmonary fibrosis, according to results ...

In addition, both FVC and 6-minute walk distance are reliable, valid, and responsive measures of disease status and independent predictors of the risk of death among patients with idiopathic ...

The FVC curves separated shortly after randomization and continued to diverge up to week 52 (Fig. S4). Sensitivity analyses to assess assumptions made in the primary analysis are shown in the ...

The rate of forced vital capacity (FVC) decline in patients with idiopathic pulmonary fibrosis (IPF) is 10 times faster than in healthy individuals, predicting disease severity and survival, says ...

The track is pulled from FVC’s debut EP Walking, to be released next month. Listen below. The Walking EP will be self-released 11/20. Pre-order it here. Cady Siregar Subscriber lallanadelrey.